Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Ítems similars

• The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
  per: Okamoto, Isamu, et al.
  Publicat: (2010)
• Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
  per: Tokudome, Nahomi, et al.
  Publicat: (2020)
• ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
  per: Azuma, Koichi, et al.
  Publicat: (2018)
• Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
  per: Imamura, Fumio, et al.
  Publicat: (2016)
• Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib
  per: Takeda, Masayuki, et al.
  Publicat: (2014)